Bladder/Urothelial

URCC 18007

Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue

---

A031702 (Penile Cohort Suspended 3/13/20, Miscellaneous GU Tract Variants Cohort suspended 7/20/20, Small Cell Carcinoma/ Neuroendocrine of the Bladder Cohort suspended 4/21/21, Adenocarcinoma of the Bladder Cohort Closed 11/9/20, Renal Medullary Cohort suspended 6/23/21, Sarcomatoid Renal Cell Carcinoma suspended 8/12/21, Cohort C: Squamous Cell Carcinoma of the Bladder temporarily suspended 4/7/22 )

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors

---

A031701

A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

---